Jeremy

Jeremy is 29 years old and has been diagnosed with ADPKD by a kidney ultrasound. Jeremy is at risk for rapid disease progression, as indicated by the following risk factors: being male, urologic events before age 35, and family history of ESKD by age 58. Let's take a closer look with some prognostic tools to confirm the risk of rapid disease progression and assess how rapidly his disease may progress.1,2

  • Age29
  • Height6'1"
  • Weight179 lbs
  • SexM
  • Race (AA/O)AA

Baseline Assessment2-6

  • Serum creatinine (mg/dL)1.21
  • eGFR (mL/min/1.73m2)80.4
    1
  • Ultrasound kidney length (cm)Not obtained
  • Hypertension before 35?Not yet observed
  • Urological event before 35?Yes
  • Family members with ESKD?Yes (50 yrs)
    3
  • MutationsNot available
  • PROPKD ScoreNot available
  • htTKV (mL/m)Perform MRI/CT
  • Other risk factorsNone
  • ADPKD Imaging ClassificationMRI or CT needed
    4

Disease Progression2,3,5-10

Kidney Size (height adjusted Total Kidney Volume)
Normal htTKV range: 150-250Years2035mL/m0500100015002000
2
Kidney function (eGFR): 76.4 mL/min/1.73m2
CKD 1CKD 2CKD 3CKD 4CKD 5/ESRDYears2035mL/min/1.73m²0102030405060708090100
20
35

Years

Click on the flags below to walk through an assessment that confirms risk of rapid disease progression and assesses how rapidly Jeremy’s disease may progress

ADPKD=autosomal dominant polycystic kidney disease; ESKD=end stage kidney disease; AA=African American; O=other; eGFR=estimated glomerular filtration rate; PKD=polycystic kidney disease; htTKV=height-adjusted total kidney volume; MRI=magnetic resonance imaging; CT=computed tomography; CKD=chronic kidney disease.
References:
  1. Schrier RW, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25:2399-2418.

  2. Gansevoort RT, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337-48.

  3. Wetzels JFM, et al. Age- and gender-specific reference values of estimated GFR in caucasians: the Nijmegen biomedical study. Kidney Int. 2007;72:632-637.

  4. Cornec-Le Gall E, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942-951.

  5. 5. Irazabal MV, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160-172.

  6. Imaging classification of ADPKD: a simple model for selecting patients for clinical trials. http://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754. Accessed January 09, 2019.

  7. 7. Cheong B, et al. Normal values for renal length and volume as measured by magnetic resonance imaging. Clin J Am Soc Nephrol. 2007;2:38-45.

  8. 8. Levey AS, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.

  9. 9. PKD Charity. Fast Facts about ADPKD. The Polycystic Kidney Disease Charity. 2017. https://pkdcharity.org.uk/about-adpkd/just-diagnosed/fast-facts-about-adpkd Accessed January 09, 2019.

  10. 10. Rangan GK, et al. Autosomal dominant polycystic kidney disease: a path forward. Semin Nephrol. 2015;35(6):524-537.

The information provided on the ADPKDsim website is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis.

Health care professionals should use their independent judgment when reviewing the ADPKDsim's educational resources. Users seeking medical advice should consult with a health care professional.